BioPharma Dive 2 jun 2026 Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
BioPharma Dive 2 jun 2026 Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
BioPharma Dive 2 jun 2026 ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer
BioPharma Dive 31 may 2026 ‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer